Navigation Links
Global Immunology Market Will Hit $74.2 Billion by 2022, says GBI Research
Date:1/28/2016

LONDON, January 28, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Global Immunology Market to 2022 - states that the global immunology treatment market is set to expand from the $61.5 billion in 2015 to an estimated $74.2 billion in 2022, despite the imminent expiry of a host of immunology treatments.

The immunology therapeutic arena's Compound Annual Growth Rate (CAGR) will equal a relatively stable 2.71%, due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline.

Managing Analyst Dominic Trewartha says: "This market is a lucrative area as up to 7% of western populations are thought to be affected by chronic immunological disorders. Consequently, the pharmaceutical pipeline for immunology is considerable, with 1,896 products currently in active development.

"While 85 of these are in Phase III of the process, it must be acknowledged that 73% of these pipeline products are in early developmental stages."

GBI Research's study suggests there are a number of prospective products expected to achieve strong annual revenues during the forecast period, although these are not anticipated to achieve revenues comparable to those generated by the current strongest-selling immunology products.

Trewartha explains: "To date, the most clinically and commercially effective drugs have been in a class of compounds known as monoclonal Antibodies (mAbs), which includes blockbuster products such as Humira (adalimumab) and Remicade (infliximab).

"APB-501, a biosimilar of Humira, which was the best-selling drug of 2014 worldwide, is anticipated to generate annual revenues of almost $1 billion by 2022, making it an exceptionally strong-performing non-patented drug."

The analyst adds that while the immunology therapeutics market is a very commercially active area, with a number of exceptionally high-selling products present, revenues for these key drugs are expected to undergo a steady decline towards the end of the period.

Trewartha concludes: "GBI Research believes that revenues for immunology therapeutics will only significantly decline in the long term, beyond the forecast period. This is due to the protective effect of the practical and regulatory challenges in fielding biosimilar products, which reduces the impact of patent expiries on biologics, compared with small molecules."

Sample pages of GBI Research's report Global Immunology Market to 2022 are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on: +44-161-359-5817

Connect with GBI Research on social media for the latest healthcare market updates:Facebook | LinkedIn | Twitter


'/>"/>
SOURCE GBI Research
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
3. Global Regulatory Milestones for Invibio Biomaterial Solutions
4. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
5. Global Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) - 2013 Market Report
6. Lucintel's Analysis of Global Catalysts Industry: Chemical and Automobile Industries Play Crucial Role in Growth
7. Global Biochips and Microarrays 2013 Market Report
8. Global Bio-implants Market 2012-2016 New Research Report Now Available at MarketResearchReports.biz
9. USP Global Fellowship Awards Program Call for Applications
10. Medical Gases and Equipment Market is Expected to Reach USD 9 Billion Globally in 2018: Transparency Market Research
11. Global Food Safety Testing Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2019)... ... August 06, 2019 , ... The San Diego ... launching the biweekly SDBN BUZZ podcast focused on connecting the region’s biotech community ... serve to promote the region and attract external employers, investors, scientists, and others ...
(Date:8/6/2019)... DEERFIELD, Ill. (PRWEB) , ... August 05, 2019 ... ... announced that Jason Casarella has been recognized as a distinguished leader by PharmaVOICE ... is featured in an article in the magazine’s July/August special issue. , As ...
(Date:8/4/2019)... ... 2019 , ... Cirtec Medical Corporation, a strategic outsourcing partner for complex medical ... construction on a 30,000 sq. ft. manufacturing facility in the Coyol free zone, ... facility, which is expected to be fully operational by the end of the year, ...
(Date:7/26/2019)... , ... July 25, 2019 , ... ... leaders through off-the-record collaboration and dialogue, today announces its Boston BD ... Hotel. As part of Biotech Week Boston , the event provides an ...
Breaking Biology Technology:
(Date:8/14/2019)... , ... August 14, 2019 , ... Join Jonathan Riek, ... session on Tuesday, September 10, 2019 at 1pm EDT to learn about two ... effective management. , NAFLD is the most common diffuse liver disease, with a ...
(Date:8/14/2019)... ... ... of Veterinary Medical Center of Fort Mill has recently begun providing VetStem ... geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis in his shoulders, hips, ... weak, and he struggled to play fetch and other games with his family. He ...
(Date:8/6/2019)... ... , ... Keck Graduate Institute (KGI) President Sheldon Schuster has announced Martin Zdanowicz ... “Dean Zdanowicz is highly regarded as an innovative leader who prioritizes student success and ... choice to build on the success of the KGI School of Pharmacy and Health ...
Breaking Biology News(10 mins):